Published in final edited form as:

Z Naturforsch C. 2008 ; 63(5-6): 371–382.

Enzymatic Inhibitory Activity and Trypanocidal Effects of Extracts and Compounds from *Siphoneugena densiflora* O. Berg and *Vitex polygama* Cham

Margareth B. C. Gallo^{a,*}, Anna Sylvia F. Marques^a, Paulo C. Vieira^a, Maria Fátima das G. F. da Silva^a, João B. Fernandes^a, Márcio Silva^b, Rafael V. Guido^b, Glaucius Oliva^b, Otávio H. Thiemann^b, Sérgio Albuquerque^c, and Alan H. Fairlamb^d

^aDepartamento de Química, Universidade Federal de São Carlos, CP 676, 13565-905, São Carlos-SP, Brazil. Fax: +55-16-33518350. margareth.gallo@gmail.com

^bInstituto de Física de São Carlos, Universidade de São Paulo, CP 369, 13560-970, São Carlos-SP, Brazil

^cFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto-SP, Brazil

^dDivision of Molecular Parasitology & Biological Chemistry, University of Dundee, Dundee DD1 4HN, UK

Abstract

Hexanic, methanolic, and hydroalcoholic extracts, and 34 isolated compounds from *Vitex polygama* Cham. (Lamiaceae, formerly Verbenaceae) and *Siphoneugena densiflora* O. Berg (Myrtaceae) were screened for their trypanocidal effects on bloodstream forms of *Trypanosoma cruzi* and *T. brucei*, as well as for their enzymatic inhibitory activities on glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) and trypanothione reductase (TR) enzymes from *T. cruzi* and adeninephosphoribosyl transferase (APRT) enzyme from *Leishmania tarentolae*. In general, polar extracts displayed strong effects and some of the tested compounds have shown good results in comparison to positive controls of the bioassays.

Keywords

Myrtaceae; *Trypanosoma*; *Leishmania*

Introduction

Siphoneugena densiflora O. Berg commonly known as Uvatinga belongs to the family Myrtaceae and occurs in grasslands (“campos rupestres”), deciduous forests (“cerradões”) and gallery forests in Goiás, Distrito Federal, Minas Gerais and São Paulo States of Brazil. This plant takes part in a genus comprising only nine species; two of them are vulnerable to extinction in São Paulo State (Programa Biotá FAPESP, 2007) and one species, *S. delicata*, has been recently described (Sobral and Proença, 2006). *S. densiflora* has been biologically and chemically researched by our group (Gallo *et al.*, 2006a, b, c) since neither data about it could be found in the literature nor popular use has been registered.

Vitex polygama Cham. (Lamiaceae, formerly Verbenaceae) is a widespread and well-known Brazilian species which occurs mainly in the states of Minas Gerais, Espírito Santo, Rio de Janeiro and São Paulo, and is commonly called “Tarumã”. Its leaf tea is used in folk medicine to treat kidney infections (Rodrigues, 2001; Gallo *et al.*, 2008). Several of its compounds had already been characterized and bioassayed (Leitão *et al.*, 1997; Leitão and Delle Monache, 1998; Santos *et al.*, 2001; Mensor *et al.*, 2001), but none was regarded as neither potential trypanocidal nor enzyme inhibitor.

Trypanosomiasis and leishmaniasis are major diseases in developing countries which continue to infect millions of people and are responsible for a mortality rate of over one million per year. At present, only ineffective, impractical or severely toxic chemotherapeutic agents, requiring a complicated regimen, are available for the treatment of these infections (WHO, 2007); hence there is a pressing need to find novel antiprotozoal agents.

Trypanosomatids have no functional tricarboxylic acid cycle, and their bloodstream forms are highly dependent on glycolysis to the stage of pyruvate as sole energy supply. Trypanosome glycolysis occurs in a specific microbody called glycosome. Accordingly, the inhibition of enzymes of this physiologically important metabolic pathway should deprive the parasite of the energy necessary for survival (Oppenheimer and Michels, 2001). The glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) enzyme of *Trypanosoma cruzi* catalyzes the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate to 1,3-bis-phosphoglycerate in the presence of NAD⁺ and inorganic phosphate. The *in silico* modeling of this pathway has indicated this catalyzed reaction as one of the preferred steps for inhibition (Bakker *et al.*, 2000). In addition, Trypanosomatidae have dithiol trypanothione [bis(glutathionyl)spermidine]-conjugated enzymes, specially trypanothione reductase (TR) (Fairlamb *et al.*, 1995), that helps to protect the parasites from oxidative stress by maintaining an intracellular reducing milieu through reduction of the N¹,N⁸-(bisglutathionyl)-spermidine conjugate trypanothione (T[S]₂) to dihydrotrypanothione (T[SH]₂). TR participates in the inactivation of potentially damaging radicals and reactive oxygen species, and is re-oxidized to (T[S]₂) in the process. The essential role of TR in the parasite thiol metabolism and its absence from the mammalian host render the enzyme a highly attractive target for drug development against trypanosomatids (Hamilton *et al.*, 2003).

The genus *Leishmania* owns three enzymes involved in the recycling of purine nucleotides by the salvage pathway. One of them, adeninephosphoribosyl transferase (APRT), is responsible for catalyzing the conversion of adenine and α -D-5-phosphoribosyl-1-pyrophosphate (PRPP) into adenosine-5-monophosphate (AMP) and pyrophosphate (PPi) by anomeric inversion of the ribofuranose ring (Musick, 1981). APRT and gGAPDH enzymes reveal differences in the amino acid sequence when compared to corresponding mammalian enzymes, which should allow the development of selective inhibitor compounds.

In our investigation for enzymatic inhibitors and trypanocidal agents to be used against parasitic protozoa, we have screened hexanic, methanolic, and hydroalcoholic extracts, as well as 34 isolated compounds from the aforementioned plants for their trypanocidal effects on bloodstream forms of *Trypanosoma cruzi* and *T. brucei*. In addition, the inhibitory activities, either on gGAPDH and TR enzymes from *T. cruzi* or APRT enzyme from *Leishmania tarentolae*, were assessed.

Materials and Methods

Plant material

Vitex polygama Cham. (Lamiaceae) and *Siphoneugena densiflora* O. Berg (Myrtaceae) were collected in July 2000 in the city of Poços de Caldas, Minas Gerais, Brazil. The plants were authenticated by Dr. Fátima Regina Salimena-Pires, a taxonomic botanist from Universidade Federal de Juiz de Fora (UFJF), and Dr. Marcos Sobral from Universidade Federal de Minas Gerais (UFMG), respectively. Voucher specimens are deposited at the herbarium of Faculdade de Filosofia, Ciências e Letras of Universidade de São Paulo, campus Ribeirão Preto (SPFR), Brazil, under the acquisition number 9968, and at the Herbarium of Botany Department, Universidade de São Paulo, São Paulo, Brazil.

Extraction procedures

Extracts as well as compounds **1** to **3**, **6**, **7**, **9**, **11** to **13**, **20** to **22**, **28** to **34** were obtained in conformity with formerly described procedures (Gallo *et al.*, 2006a, b, c, 2008).

Isolation of compound 4 from the methanolic extract of stem of *Siphoneugena densiflora* (SD-MS)—A quantity of 60.7 g of SD-MS was submitted to liquid-liquid partition using solvents of increasing polarity (dichloromethane, ethyl acetate and *n*-butanol). The corresponding dichloromethane layer (SD-DMS, 1.62 g) was chromatographed over Sephadex LH-20 (60.0 × 2.0 cm) using a gradient elution from dichloromethane/hexane (1:1 by volume) to methanol (100%), resulting in 35 fractions of 20 mL each, which were pooled into 10 fractions (D1 to D10) according to their composition, determined by thin layer chromatography and visualized under UV light and spraying with colour reagent. Fraction D8 (600.0 mg) was rechromatographed over Sephadex LH-20 (23.0 × 3.0 cm) employing a step gradient from dichloromethane (100%), dichloromethane/acetone (80:20 by volume) and methanol (100%). A total of 52 fractions of 20 mL each was collected and combined in agreement with the fractions similarities, affording 16 fractions (D8a to D8p). Fraction D8i was identified as compound **4** (12.0 mg).

Isolation of compounds 5, 14, 15, 16, 17, 19, 24, 25, 26 and 27 from a dichloromethane layer of the methanolic extract of leaves of *Vitex polygama* (VP-DML)—A quantity of 38.1 g of VP-ML was submitted to liquid-liquid partition using solvents of increasing polarity (dichloromethane and ethyl acetate). The corresponding dichloromethane layer (VP-DML, 15.1 g) was chromatographed on a silica gel 60 column (20.0 × 5.5 cm) and eluted in a step gradient from dichloromethane/methanol (95:5 by volume) to methanol (100%) (step A, Fig. 1). A total of 14 fractions of 125 mL each was collected and pooled into 8 fractions (L1 to L8). Fraction L4 (4.4 g) was submitted to column chromatography (CC) (16.5 × 5.5 cm) with silica gel 60 and gradient elution from hexane/ethyl acetate (70:30 by volume) to methanol (100%) (step B, Fig. 1), resulting in 15 fractions of 100 mL each, which were combined into four fractions (L4a to L4d). Fraction L4d (3.09 g) was rechromatographed on silica gel 60 (20.0 × 5.0 cm) using a step gradient from dichloromethane (100%) to methanol (100%) (step C, Fig. 1), yielding 20 fractions of 100 mL each, which were pooled into 8 fractions (L4da to L4dh). Fraction L4df (350.4 mg) was chromatographed using step C conditions with a column of 15.0 × 4.0 cm (step G, Fig. 1) to afford 15 fractions of 150 mL each, that were combined into 8 fractions (L4df1 to L4df8). Fraction L4df4 (130.8 mg) was submitted to CC (15.0 × 4.0 cm) with silica gel 60 and gradient elution from dichloromethane/ethyl acetate (90:10 by volume) to methanol (100%) (step H, Fig. 1) to afford 11 fractions of 150 mL each, that were combined into 8 fractions (L4df41 to L4df48). Fraction L4df42 (10.2 mg) was purified on silica gel (10.0 × 3.0 cm) using isocratic elution with dichloromethane/ethyl acetate (95:5 by volume; step N, Fig. 1) to afford 14 fractions of 100 mL each, that were combined into 5 fractions (L4df421

to L4df425). Fraction L4df423 was identified as compound **25**. Fraction L4df44 (89.3 mg) was submitted to step H conditions in a column of 25.0×4.5 cm (step I, Fig. 1) to yield 16 fractions of 100 mL each, that were combined into 6 fractions (L4df441 to L4df446). Fraction L4df446 (75.5 mg) was chromatographed over Sephadex LH-20 (52.0×2.0 cm) using methanol as eluent (step J, Fig. 1) to yield 31 fractions of 15 mL each, that were combined into 4 fractions (L4df446R to L4df446U). Fraction L4df446T (11.7 mg) was purified over a silica gel column (24.0×1.0 cm) using dichloromethane/ethyl acetate (90:10 by volume) as eluent (step K, Fig. 1) to yield 31 fractions of 15 mL each, that were combined into 3 fractions. Fraction 3 (L4df446Ta, 4.0 mg) was identified as compound **16**. Fraction L4df443 (26.5 mg) was submitted, consecutively, to the conditions of steps K and J (step L, Fig. 1) to afford compound **24**. Fraction L4dg (436.4 mg) was submitted repeatedly to the conditions of steps A, K and J (steps D, E and F, Fig. 1) to afford compound **19**. Fraction L4c (940.2 mg) was fractionated on silica (24.0×4.0 cm) using gradient elution with hexane/ethyl acetate (70:30 by volume) to yield 17 fractions of 100 mL each, that were combined into 7 fractions (L4c1 to L4c7; step M, Fig. 1). Fraction L4c5 (241.5 mg) was submitted to the conditions of step J to afford 27 fractions of 15 mL each, that were combined into 7 fractions (L4c5F to L4c5L; step P, Fig. 1). Fraction L4c5J (11.3 mg) was purified by a HPLC RP-ODS C18 system (step Q, Fig. 1) employing methanol isocratic elution (254 nm; flow rate of 2 mL/min; injection volume of 1 mL) to afford compound **17**. Fraction L4c5I (11.0 mg) was submitted to preparative TLC (20.0×20.0 cm, step O, Fig. 1) using dichloromethane/methanol (90:10 by volume) as eluent to yield compounds **5** and **27**. Fraction L4df5 (43.5 mg) was chromatographed on silica gel 60 (18.0×5.0 cm, step T, Fig. 1) under the elution conditions of step H. A total of 18 fractions of 50 mL was collected and pooled into 7 fractions (L4df51 to L4df57). Fraction L4df54 (20.3 mg) was chromatographed on silica gel 60 (15.0×2.5 cm, step U, Fig. 1) employing dichloromethane/ethyl acetate (70:30 by volume). A total of 10 fractions of 100 mL each was collected and pooled into 6 fractions (L4df54a to L4df54f). The constituent of fraction L4df54c was identified as compound **26** (11.7 mg). Fraction L5 (1.9 g) was subjected to CC using silica gel 60 (20.0×4.0 cm) and gradient elution from ethyl acetate (100%) to methanol (100%) (step R, Fig. 1), yielding 13 fractions of 50 mL each which were pooled into 6 fractions (L5a to L5f). Fraction L5b (608.8 mg) was chromatographed over Sephadex LH-20 (60.0×2.0 cm) using methanol as eluent for three repeated times (step S, Fig. 1) to yield fraction 4 (L5btg4, 1.0 mg) that was identified as compound **15** and fraction 5 (L5btg5, 4.0 mg) characterized as compound **14**.

Isolation of compounds 18 and 23 from a methanolic layer of the hexanic extract of leaves of *Vitex polygama* (VP-MHL)—The corresponding methanolic layer (VP-MHL, 171.0 mg) was chromatographed on a silica gel 60 column (18.0×4.5 cm) and eluted in a step gradient from dichloromethane/hexane (50:50 by volume) to methanol (100%). A total of 20 fractions of 150 mL each was collected and pooled into 7 fractions (MHL1 to MHL7). Fraction 5 (MHL5, 26.6 mg) was chromatographed over Sephadex LH-20 (52.0×3.0 cm) employing methanol as eluent to afford 31 fractions of 15 mL each, which were pooled into 7 fractions (MHL5a to MHL5g). Fraction 6 (MHL5f, 1.2 mg) was identified as compound **18** and fraction 5 (MHL5e, 4.2 mg) as compound **23**.

Isolation of compounds 8 and 10 from a dichloromethane layer of the methanolic extract of stem of *Siphoneugena densiflora* (SD-DMS)—A quantity of 1.62 g of SD-DMS was chromatographed over Sephadex-LH20 (28.0×3.0 cm) using gradient elution from dichloromethane/hexane (50:50 by volume), dichloromethane (100%), methanol/dichloromethane (50:50 by volume) to methanol (100%). A total of 34 fractions of 20 mL each was collected and pooled into 10 fractions (DMS1 to DMS10). Fraction 5 (DMS5, 75.4 mg) was rechromatographed over Sephadex-LH20 (45.0×2.0 cm) using

methanol as eluent to afford 15 fractions of 20 mL each, which were combined into 5 fractions (DMS5m to DMS5q). Fraction 5 (DMS5q, 25.9 mg) was purified by PTLC (20.0 × 20.0 cm) using dichloromethane/acetone (90:10 by volume) as eluent twice to afford compound **8** (3.4 mg). Fraction 6 (DMS6, 115.7 mg) was submitted to CC using silica gel 230–400 mesh (23.0 × 3.0 cm) employing a gradient elution from dichloromethane (100%), dichloromethane/ethyl acetate to methanol (100%). A total of 56 fractions of 20 mL each was collected and pooled into 11 fractions (DMS61 to DMS611). Fraction 9 (DMS69, 10.4 mg) was purified by PTLC (20.0 × 20.0 cm) using dichloromethane/acetone (90:10 by volume) as eluent to afford compound **10** (5.0 mg).

***T. cruzi* gGAPDH inhibitory activity**

The enzymatic activity of *T. cruzi* gGAPDH and the inhibitory activities of extracts and compounds against this enzyme have been determined according to an earlier reported procedure (Vieira *et al.*, 2001). The 50% inhibitory concentration (IC₅₀), *i.e.*, the concentration necessary to inhibit 50% of enzyme activity, was estimated from graphically plotted dose-response curves by making rate measurements for at least five inhibitor concentrations, using the nonlinear curve-fitting program SigmaPlot 2001 7.0. Statistical error limits on the IC₅₀ values have been calculated in amount to 10% or less. The coumarin chalepin was used as positive control (IC₅₀ = 55.5 μM).

***L. tarentolae* APRT inhibitory activity**

APRT cloning, expression, and purification have been determined according to earlier described procedures (Thiemann *et al.*, 1998). The APRT activity has been determined by spectrophotometric measurements of the formation of AMP at 259 nm after 60 s. The reaction mixture contained, in a final volume of 1.0 mL, 0.01 mM adenine, 0.5 mM PRPP, 5 mM MgCl₂, 100 mM Tris-HCl [2-amino-2-(hydroxymethyl)-1,3-propanediol-hydrochloride], pH 7.4, and 3.8 μL APRT solution. The reaction started by the addition of enzyme. The specific activity of the enzyme and the inhibitory activity of compounds and extracts have been calculated in agreement with the literature (Vieira *et al.*, 2001).

***T. cruzi* TR inhibitory activity**

Enzyme activity and assay were performed according to prior descriptions (Hamilton *et al.*, 2003). Clomipramine (Novartis) was used as positive control [IC₅₀ = 2.72 μM (personal communication, Alan Fairlamb)]. The IC₅₀ value was determined by microplate assays in serial two-fold dilutions of the test compound. The data were processed using the GraFit version 4.5 Program (written by R. J. Laetherbarrow, Univ. London Imperial Coll. Sci. Technol. & Med., Dept. Chem., Biol. & Biophys. Chem. Sect., London SW7 2AZ, England) in order to obtain the IC₅₀ values, and the results were fitted into the equation

$$Y = \{ \text{Range} / [1 + (X/\text{IC}_{50})^s] \} + \text{Background},$$

where Y is the absorbance, X the concentration of the test compound (in μM), Range the Y axis scale, Background the zero control and s the slope factor (s = 1).

***T. brucei* cell culture and cytotoxicity assay**

Bloodstream forms of *T. brucei*, strain 427 wild type, were grown in HMI-9 medium with 10% serum following the published protocol (Hirumi and Hirumi, 1989). The effect of compounds on the viability of bloodstream forms of *T. brucei* was evaluated using the Alamar Blue® assay (Räz *et al.*, 1997). Petamidine was used as positive control (IC₅₀ = 14 nm). In general, compounds were tested at a concentration of 100 μM.

T. cruzi cytotoxicity assay

The assay was carried out using blood infected with trypomastigotes of *T. cruzi* “Y” strain collected by cardiac puncture in experimentally infected male Swiss albino mice on the parasitemic peak (seventh day) and diluted with normal murine blood to $2 \cdot 10^6$ trypomastigotes/mL. The assay was performed in triplicate on titration microplates (96 wells) containing 387.5 μ L of diluted infected blood and solutions of extracts or compounds in DMSO to acquire final concentrations of 4 mg/mL, 500 μ g/mL, 250 μ g/mL and 100 μ g/mL. The plates were incubated at 4 °C, and the number of parasites counted after 24 h. Negative and positive controls containing infected blood with either 2.5% DMSO or gentian violet ($IC_{50} = 31 \mu\text{g/mL}$ or $76 \mu\text{M}$) were run in parallel. The results were expressed as percentage of lysis of trypomastigote forms compared to the DMSO control. DMSO at 2.5% did not interfere with the parasite survival.

Results and Discussion

Identification of compounds

Fig. 2 shows the structures of isolated and tested compounds from *S. densiflora*: quercetin (1); quercitrin (2); gallic acid (3); arjunolic acid (4); vanillic acid (5); sitosterol (6); syringic acid (7); 2,4,6-trimethoxybenzoic acid (8); ellagic acid (9); 5-hydroxymethyl-2-furancarboxaldehyde (10); casuarinin (11); castalagin (12); ellagic acid 4-*O*- α -l-rhamnopyranoside (13); and from *V. polygama*: luteolin (14); 3-*O*-methylquercetin (15); chrysoeriol (16); 3,3'-*O*-dimethylquercetin (17); 3,7,4'-*O*-trimethylkaempferol (18); acacetin (19); isoorientin (20); schaftoside (21); carlinoside (22); penduletin 4'-*O*-methyl ether (23); 2 α ,3 α -dihydroxyolean-12-en-28-oic acid (24); oleanolic acid (25); 2 α ,3 α ,19 α -trihydroxyurs-12-en-28-oic acid (26, euscaphic acid); *p*-hydroxybenzoic acid (27); 20-hydroxyecdysone (28, polypodine A); polypodine B (29); stachysterone (30); shidasterone (31); metacrylic acid (32); caffeoyl 6-*O*- β -D-glucopyranoside (33); sitosterol 3-*O*- β -D-glucopyranoside (34, daucosterol). The structures of the compounds were elucidated by comparison of their spectral data (^1H NMR, ^{13}C NMR, DEPT, HMBC, HSQC, ^1H - ^1H COSY, IE-MS or ESI-MS) with earlier published data (see references in Tables I and II).

Trypanocidal activity

Among the 21 extracts and 13 partition fractions tested against trypomastigote forms of *T. cruzi*, 15 revealed significant activities (> 60%, Table III) and were considered as promising sources of active substances.

Partition of VP-HL produced fractions with poorer activities (Table III). ^1H NMR analysis of VP-HHL (53%) showed characteristic signals of hydrocarbons and fatty acids. VP-DHL (38%), when submitted to column chromatography, yielded a fraction containing a mixture of steroids which was responsible for 93% of Tc lysis at 500 μ g/mL (this information is not displayed in the table). VP-EHL (36%) yielded compound **18** (31%), and VP-MHL (52%) afforded compounds **18** and **23** (16%).

VP-DML, after fractionation, afforded compounds **16**, **17**, and a mixture of flavonoids containing quercetin 3-*O*- β -D-glucopyranoside and quercetin 4'-*O*- β -D-glucopyranoside, which caused 97% Tc lysis at 500 μ g/L. The same mixture inhibited the gGAPDH activity by 92% at 100 μ g/mL (this information is not displayed in the table), which may explain the mechanism of action of the mixture on the trypomastigote forms of the parasite. **16** performed a better activity against *T. cruzi* (33%, Table II) in comparison with compound **14** (27%), indicating that *O*-methylation of the 3'-hydroxy group was important to improve the activity.

VP-BHAL showed a good trypanocidal activity against *T. cruzi* (60%, Table III), however, the compounds isolated from this fraction did not. Compound **33** (11%, 1.5 mM, Table II) was much less active than its aglycone tested previously (IC₅₀ 2.1 mM, Graef *et al.*, 2005), showing that the glycoside moiety, making the molecule more polar, had a bad influence on the biological action.

The polar extracts from *S. densiflora* (SD-HAS, SD-MT, SD-HAT, SD-MR, and SD-HAR, Table III) exhibited a strong effect on *T. cruzi*; on the other hand, compounds isolated from them did not (**3**, **6**, **7**, **9**, **11**, **12** and **13**; Table I). Maybe the compound(s) responsible for the original extract activity had not been identified yet.

The outcomes from triterpenes **4** (Table I), **24**, **25** and **26** (Table II) point out a clear correlation between increasing number of hydroxy groups and higher activity, which justifies a meticulous investigation on structure-activity relationships in this case.

All the substances tested against *T. brucei* were inactive, perhaps because of the low concentration (100 μ M) tested in contrast to the concentration tested on *T. cruzi* (500 μ g/mL, see Tables I and II).

gGAPDH inhibition

On the whole, 26 extracts and subfractions were tested. Eleven of them, the most polar (SD-methanolic and hydroalcoholic extracts), showed outcomes above 70% (Table III), and the majority belonged to *S. densiflora* (SD). The ascription of such activities to the hydrolysable tannins **11**, **12**, **13**, and ellagic acid (**9**) may be considered due to the low IC₅₀ values accomplished by these compounds (Table I).

Among the flavonoids, the simple and highly oxidized flavonol quercetin (**1**) was the most active. The flavone luteolin (**14**), without a hydroxy group at C-3, had a reduced performance. Though, its activity seemed to be improved by the introduction of the methoxy group at position C-3 (**15**) or C-3' (**16**), the presence of two or more methoxy groups at the flavone skeleton did significantly lower the inhibitory activity of the three tested enzymes (for comparison, see activities of compounds **17**, **18** and **23** in Table II). The *O*-glycosylated flavonol quercitrin (**2**) had a minor outcome in contrast to its aglycone **1**. Lio *et al.* (1985) observed the same behaviour with these compounds on xanthine oxidase, concluding that glycosylated derivatives are more hydrophilic and bulky, what reduces their contact with the active site of the enzyme. This observation fits with the small activities also performed by compounds **21** and **22** (Table II). The triterpenes were no efficient inhibitors of the gGAPDH enzyme neither a mixture of them (see Tables I and II). An unseparated mixture of lupeol, α -amyrin and β -amyrin, isolated from the dichloromethane layer of the methanolic extract of leaves from *S. densiflora* (SD-DML), tested at 200 μ M, was inactive (this information is not shown in the table). At a similar concentration, a mixture of compound **24** and its isomer 2 α ,3 β -dihydroxyurs-12-en-28-oic acid, isolated from VP-DML, was also inactive, while compound **24** inhibited 44% of the enzyme activity (Table II).

APRT inhibition

From 17 extracts and subfractions tested, eight presented results greater than 60%. Several could not be screened because they absorbed at the same wavelength used in the bioassay. The activity of the methanolic extract from leaves of *S. densiflora* was increased after fractionation (from 74 to 90%, Table I). Furthermore, quercetin (**1**) as well as quercitrin (**2**), from the ethyl acetate layer (SD-EML), showed inhibitory activities similar to their original extracts (97 and 89%, respectively, Table I). Altogether, flavonoids and triterpenes had

activities similar to those performed on gGAPDH (Tables I and II). When analyzing the results displayed by ecdysteroids, we can notice that their activities were strictly linked to the number of hydroxy groups. Accordingly, compound **29**, bearing an extra hydroxy group in relation to **28** and two in relation to **30**, was twice more active than **28** and seven times more than **30** (Table II).

TR inhibition

All tested substances were practically inactive toward the TR enzyme except for casuarinin (**11**) and castalagin (**12**) which performed an IC₅₀ value of 179.3 μM on enzyme inhibition, although this result is not promising in comparison with clomipramine, the positive control.

Acknowledgments

The authors are grateful to Dr. Marcos Sobral (UFMG) and Fátima Regina Salimena-Pires (UFJF) for botanical identifications, to ALCOA Alumínio S/A for facilitating the plant collections, to Ahilan Saravanamuthu for supplying TR enzyme, and to Dr. John Lee Richardson for valuable discussions. This research has been supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).

References

- Bakker BM, Westerhoff HV, Opperdoes FR, Michels PAM. Metabolic control analysis of glycolysis in trypanosomes as an approach to improve selectivity and effectiveness of drugs. *Mol. Biochem. Parasitol.* 2000; 106:1–10. [PubMed: 10743606]
- Besson E, Dellamonica G, Chopin J, Markham KR, Kim M, Koh H, Fukami H. C-Glycosyl-flavones from *Oryza sativa*. *Phytochemistry.* 1985; 24:1061–1064.
- Brieskorn VCH, Riedel W. Flavonoide aus *Coleus amboinicus*. *Planta Med.* 1977; 31:308–310.
- Chiappini I, Fardella G, Menghini A, Rossi C. Flavonoids from *Dittrichia viscosa*. *Planta Med.* 1982; 44:159–161. [PubMed: 17402102]
- Davidson BS, Eisner T, Witz B, Meinwald J. Defense mechanisms of arthropods No. 87. Defensive secretion of the carabid beetle *Pasimachus subsulcatus*. *J. Chem. Ecol.* 1989; 15:1689–1697.
- Dayrit FM, Lapid MRG, Cagampang JV, Lagurin LG. Phytochemical studies on the leaves of *Vitex negundo* L. (“Lagundi”). I. Investigation of the bronchial relaxing constituents. *Philipp. J. Sci.* 1987; 116:403–410.
- Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A. Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. *Ann. Rev. Microbiol.* 1995; 46:695–729. [PubMed: 1444271]
- Gallo MBC, Rocha WC, Cunha US, Diogo FA, Silva FC, Vieira PC, Vendramim JD, Fernandes JB, Silva MFGF, Batista-Pereira LG. Bioactivity of extracts and isolated compounds from *Vitex polygama* (Verbenaceae) and *Siphoneugena densiflora* (Myrtaceae) against *Spodoptera frugiperda* (Lepidoptera: Noctuidae). *Pest. Manag. Sci.* 2006a; 62:1072–1081. [PubMed: 16953496]
- Gallo MBC, Silva FC, Vieira PC, Fernandes JB, Silva MFGF. New natural products from *Siphoneugena densiflora* Berg (Myrtaceae) and their chemotaxonomic significance. *J. Braz. Chem. Soc.* 2006b; 17:279–288.
- Gallo MBC, Beltrame FL, Vieira PC, Cass QB, Fernandes JB, Silva MFGF. Quantitative determination of 20-hydroxyecdysone in methanolic extract of twigs from *Vitex polygama* Cham. *J. Chromatogr. B.* 2006c; 832:36–40.
- Gallo MBC, Vieira PC, Fernandes JB, Silva MFGF, Salimena-Pires FR. Compounds from *Vitex polygama* active against kidney diseases. *J. Ethnopharmacol.* 2008; 115:320–322. [PubMed: 17981413]
- Grael CFF, Albuquerque S, Lopes JLC. Chemical constituents of *Lychnophora pohlii* and trypanocidal activity of crude extracts and of isolated compounds. *Fitoterapia.* 2005; 76:73–82. [PubMed: 15664466]

- Hamilton CJ, Saravanamuthu A, Eggleston IM, Fairlamb AH. Ellman's-reagent-mediated regeneration of trypanothione *in situ*: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. *Biochem. J.* 2003; 369:529–537. [PubMed: 12416994]
- Hirumi H, Hirumi K. Continuous cultivation of *Trypanosoma brucei* bloodstream forms in a medium containing a low concentration of serum protein without feeder cell layers. *J. Parasitol.* 1989; 75:985–989. [PubMed: 2614608]
- Kulkarni AD, Modak HM, Jadhav SJ, Khan R. Preparation and commercial significance of 5-hydroxymethyl-2-furancarboxaldehyde: a review. *J. Sci. Ind. Res.* 1989; 47:335–339.
- Leitão SG, Delle Monache F. 2''-*O*-Caffeoylorientin from *Vitex polygama*. *Phytochemistry.* 1998; 49:2167–2169.
- Leitão SG, Melo FPG, Delle Monache F, Gonçalves JLS, Wigg MD. Inhibitory activity of *Vitex polygama* extracts against *Herpes simplex* type-1. *Bull. Chim. Farmac.* 1997; 136:121.
- Lio M, Moriyama A, Matsumoto Y, Takaki N, Fukumoto M. Inhibition of xanthine oxidase by flavonoids by folate compounds and by amethopterin. *J. Biol. Chem.* 1985; 259:12–15.
- Mahato SB, Kundu AP. ¹³C NMR spectra of pentacyclic triterpenoids - a compilation and some salient features. *Phytochemistry.* 1994; 37:1517–1575.
- Mensor LL, Menezes FS, Leitão GG, Reis AS, Santos TC, Coube CS, Leitão SG. Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method. *Phytother. Res.* 2001; 15:127–130. [PubMed: 11268111]
- Musick WD. Structural features of the phosphoribosyltransferases and their relationship to the human deficiency disorders of purine and pyrimidine metabolism. *CRC Crit. Rev. Biochem.* 1981; 11:1–34. [PubMed: 7030616]
- Opperdoes FR, Michels PAM. Enzymes of carbohydrate metabolism as potential drug targets. *Int. J. Parasitol.* 2001; 31:482–490. [PubMed: 11334933]
- Pettit GR, Cragg GM, Singh SB. Constituents of *Combretum caffrum*. *J. Nat. Prod.* 1987; 50:386–391. [PubMed: 3668557]
- Programa Biota FAPESP. List of species in extinction in São Paulo State. Brazil: 2007. <http://www.biota.org.br/info/wap/lista1qrs.html>
- Räz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R. The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (*T. brucei rhodesiense* and *T. brucei gambiense*) *in vitro*. *Acta Tropica.* 1997; 68:139–147. [PubMed: 9386789]
- Rodrigues, LA. Estudo Florístico e Estrutural da Comunidade Arbustiva e Arbórea de uma Floresta em Luminárias, MG, e Informações Etnobotânicas da População Local. Universidade Federal de Lavras, MG; Brazil: 2001. p. 190 Master's Dissertation
- Roitman JN, James LF. Chemistry of toxic range plants. Highly oxygenated flavonol methyl ethers from *Gutierrezia microcephala*. *Phytochemistry.* 1985; 24:835–848.
- Russel KM, Molan PC, Wilkins AL, Holland PT. Identification of some antibacterial constituents of New Zealand Manuka honey. *J. Agric. Food Chem.* 1990; 38:10–13.
- Sakushima A, Coskun M, Maoka T. Hydroxybenzoic acids from *Boreava orientalis*. *Phytochemistry.* 1995; 40:257–261.
- Santos TC, Delle Monache F, Leitão SG. Ecdysteroids from two Brazilian *Vitex* species. *Fitoterapia.* 2001; 72:215–220. [PubMed: 11295296]
- Sobral M, Proença CEB. *Siphoneugena delicata* (Myrtaceae), a new species from the montane Atlantic forest of southeastern Brazil. *Novon.* 2006; 16:530–532.
- Southwick L, Mabry TJ, Averett J, Powell AM. Penduletin 4'-*O*-methyl ether from *Perityle vaseyi*. *Phytochemistry.* 1972; 11:2351.
- Suksamrarn A, Sommechai C. Ecdysteroids from *Vitex pinnata*. *Phytochemistry.* 1993; 32:303–306.
- Suttanut K, Sripanidkulchai B, Yenjai C, Jay M. Simultaneous identification and quantitation of 11 flavonoid constituents in *Kaempferia parviflora* by gas chromatography. *J. Chromatogr. A.* 2007; 1143:227–233. [PubMed: 17266972]
- Takeara R, Albuquerque S, Lopes NP, Lopes JLC. Trypanocidal activity of *Lychnophora staavioides* Mart. (Vernonieae, Asteraceae). *Phytomedicine.* 2003; 10:490–493. [PubMed: 13678232]

- Thiemann OH, Alfonzo JD, Simpson L. Cloning and characterization of *Leishmania tarentolae* adenine phosphoribosyltransferase. Mol. Biochem. Parasitol. 1998; 95:141–146. [PubMed: 9763296]
- Vieira PC, Mafezoli J, Pupo MT, Fernandes JB, Silva MFGF, Albuquerque S, Oliva G, Pavão F. Strategies for the isolation and identification of trypanocidal compounds from the Rutales. Pure Appl. Chem. 2001; 73:617–622.
- WHO (World Health Organization). 2007. [http:// www.who.int/tdr](http://www.who.int/tdr)

Fig. 1. Fluxogram of isolation of compounds **5**, **14** to **17**, **19**, **24** to **27** from *Vitex polygama*.

Fig. 2.
Structures of compounds isolated from *V. polygama* and *S. densiflora*.

Table I
In vitro antiprotozoal and enzymatic inhibitory activities of compounds from *Siphonogena densiflora*.

Compound	Extract origin	% lysis Tc [mM]	% inhibition gCAPDH (200 μ M)	% inhibition APRT (100 μ M)	% inhibition TR (100 μ M)	% growth inhibition Tb (100 μ M)	Reference
1	SD-EML	34 (1.7)	91 ^a	97	NT	NT	Gallo et al., 2006a
2	SD-EML	30 (1.1)	19	89	4	I	Gallo et al., 2006a
3	SD-EML SD-MR SD-MS	19 (2.9)	I	I	5	I	Gallo et al., 2006b
4	SD-MS	90 (1.0) 61 (0.5) 9 (0.2)	I	13	NT	NT	Mahato and Kundu, 1994
5	SD-MS	NT	I	I	NT	NT	Sakushima et al., 1995
6	SD-MR	NT	I	I	NT	NT	Gallo et al., 2006b
7	SD-EML SD-MR	16 (2.5)	I	I	14	I	Gallo et al., 2006a
8	SD-MS	NT	I	24	NT	NT	Russel et al., 1990
9	SD-MR	41 (1.7)	90 ^b	80	NT	NT	Gallo et al., 2006a
10	SD-MS	NT	I	I	46	I	Kulkarni et al., 1989
11	SD-MS SD-MR SD-EML	28 (0.5)	c	d	87 ^g	I	Gallo et al., 2006a
12	SD-MS SD-MR	11 (0.5)	e	f	87 ^g	I	Gallo et al., 2006a
13	SD-MS SD-MR SD-HAS	12 (1.1)	86 (239 μ M) 33 (119 μ M)	NT [*]	NT	NT	Gallo et al., 2006a

NT, not tested; NT*, compound absorbed at the same wavelength of enzyme assay; I, inactive; Tc, trypanomastigotes forms of *Trypanosoma cruzi*; Tb, bloodstream forms of *T. brucei*; TR, trypanothione reductase.

^aIC₅₀ = (24 $\pm$ 3.9) μ M.

^bIC₅₀ = (25 $\pm$ 2.2) μ M.

^cIC₅₀ = (1.8 $\pm$ 1.5) μ M.

^dIC₅₀ = (1.8 $\pm$ 1.5) μ M.

$$^{WM}_f(5.1 \pm 1.5) = 0.5C_{1g}^{WM}$$

$$^{WM}_f(3.3 \pm 2.3) = 0.5C_{1f}^{WM}$$

$$^{WM}_g(7.5 \pm 0.7) = 0.5C_{1g}^{WM}$$

Table II
In vitro antiprotozoal and enzymatic inhibitory activities of compounds from *V. polygama*.

Compound	Extract origin	% lysis Tc [mm]	% inhibition gGAPDH (200 μ M)	% inhibition APRT (100 μ M)	% inhibition TR (100 μ M)	% growth inhibition Tb (100 μ M)	Reference
14	VP-DML	27 (1.7) ^a	56	40	46	I	Gallo <i>et al.</i> , 2008
15	VP-DML	NT ^b	73 ^c	84	NT	NT	Roitman and James, 1985
16	VP-DML	33 (1.7)	75	80	18	I	Brieskorn and Riedel, 1977
17	VP-DML	NT	37	25	NT	NT	Chiappini <i>et al.</i> , 1982
18	VP-MHL VP-EHL	31 (1.5)	41 (305 μ M)	NT	NT	NT	Suttanut <i>et al.</i> , 2007
19	VP-DML	NT	22	16	NT	NT	Petit <i>et al.</i> , 1987
20	VP-BHAL	13 (1.1)	63	63	17	I	Gallo <i>et al.</i> , 2008
21	VP-BHAL	NT	10	47	5	I	Besson <i>et al.</i> , 1985
22	VP-BHAL	NT	7	14	NT	NT	Besson <i>et al.</i> , 1985
23	VP-MHL	16 (1.4)	20	12	NT	NT	Southwick <i>et al.</i> , 1972
24	VP-DML	76 (1.1) 5 (0.5)	44	71	NT	NT	Mahato and Kundu, 1994
25	VP-DML	38 (1.1)	40	68	NT	NT	Mahato and Kundu, 1994
26	VP-DML VP-DMT	90 (1.0) 87 (0.5) 16 (0.2)	I	10	29	I	Mahato and Kundu, 1994
27	VP-DML	NT	I	I	NT	NT	Dayrit <i>et al.</i> , 1987
28	VP-EMT	71 (1.0) 70 (0.5) 4 (0.2)	6	41	NT	NT	Suksamrarn and Somdechai, 1993
29	VP-EMT	NT	27	84	NT	NT	Gallo <i>et al.</i> 2006a
30	VP-EMT	NT	10	12	NT	NT	Gallo <i>et al.</i> 2006c
31	VP-EMT	NT	14	58	NT	NT	Gallo <i>et al.</i> 2006c
32	VP-AHAL	8 (5.8)	I	I	NT	NT	Davidson <i>et al.</i> , 1989
33	VP-BHAL	11 (1.5)	I	I	11	I	Gallo <i>et al.</i> 2006a
34	VP-DML	14 (0.9)	I	40	NT	NT	Gallo <i>et al.</i> 2006b

NT, not tested; I, inactive; Tc, trypomastigotes forms of *Trypanosoma cruzi*; Tb, bloodstream forms of *T. brucei*; TR, trypanothione reductase.

^a₁C₅₀ = 132.6 mm according to Graef *et al.* (2005).

$b_{63\% \text{ lysis}} (1.7 \text{ mm})$ according to Takeara *et al.* (2003).

$$b_{IC50} = (36 \pm 9.63) \mu\text{M}.$$

Table III

In vitro antiprotozoal and enzymatic inhibitory activities of *Siphoneuena densiflora* (SD) and *Vitex polygama* (VP) extracts and fractions.

Extract (obtained amount, g) ^a	% lysis Tc (4 mg/mL)	% inhibition gGAPDH (100 µg/mL)	% inhibition APRT (50 µg/mL)
SD-HL (8.2)	82	28	NT
SD-ML (164.8)	34	74	97
SD-DML (9.5)	NT	NT	30
SD-EML (14.6)	NT	90	73
SD-BML (12.0)	NT	NT	68
SD-AML (12.5)	NT	NT	75
SD-HAL (22.1)	49	82	NT*
SD-HS (0.9)	65	I	14
SD-MS (177.6)	47	91	NT*
SD-HAS (5.5)	100	93	NT*
SD-HT (1.0)	33	I	30
SD-MT (131.1)	83	94	28
SD-HAT (5.7)	100	92	73
SD-HR (0.3)	64	26	4
SD-MR (73.2)	88	92	NT*
SD-HAR (2.4)	61	94	NT*
VP-HL (5.1)	94	NT	NT
VP-HHL (1.08)	53	I	NT
VP-DHL (1.84)	38	I	NT
VP-EHL (1.94)	36	22	NT
VP-MHL (0.19)	52	I	NT
VP-ML (40.4)	58	3	NT
VP-DML (15.1)	NT	NT	74
VP-EML (8.0)	NT	NT	62
VP-HAL (31.0)	41	81	NT
VP-EHAL (2.2)	62	I	56
VP-BHAL (12.8)	60	I	67

Extract (obtained amount, g) ^a	% lysis Tc (4 mg/mL)	% inhibition gCAPDH (100 µg/mL)	% inhibition APRT (50 µg/mL)
VP-AHAL (22.6)	40	76	NT
VP-HT (0.85)	75	I	NT
VP-MT (19.3)	28	I	NT
VP-EMT (3.9)	NT	NT	51
VP-DMT (2.6)	NT	NT	52
VP-HAT (2.3)	81	39	NT
VP-HF (1.1)	80	I	NT
VP-MF (2.0)	80	NT	26
VP-HAF (0.9)	39	NT	NT

^aH, hexane extract; HH, hexane partition of H; DH, dichloromethane partition of H; EH, ethyl acetate partition of H; MH, methanol partition of H; M, methanol partition of M; DM, dichloromethane partition of M; EM, ethyl acetate partition of M; AM, aqueous partition of M; HA, hydroalcoholic extract; EHA, ethyl acetate partition of HA; BHA, *n*-BuOH partition of HA; AHA, aqueous partition of HA; L, leaves; S, stem; T, twigs; R, root bark; F, fruit.

Tc, trypanostigotes forms of *Trypanosoma cruzi*; NT, not tested

* NT, the extract absorbed at the same wavelength of the enzyme assay and was not tested; I, inactive.